Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Phase 3sigvotatug vedotinNeutral
AI Analysis
Summary
Pfizer announced topline results from the Phase 3 SigVie-002 study evaluating sigvotatug vedotin in previously treated metastatic non-squamous non-small cell lung cancer. The article excerpt does not contain specific efficacy or safety outcome details.
Clinical Trial Data
Phase
Phase 3
Importance:8/10
Sentiment:
0.00
Phase 3lung canceroncologytopline results
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on June 22, 2026 8:07 AM